A Tale of Two Companies: Matinas Biopharma and Cytodyn
Cytodyn
Leronlimab
May 2014 first patient dosed with Pro 140
December 2019 BLA nearing completion, FDA approval expected early 2nd quarter 2020
Matinas Biopharma
MAT9001
Dec 2014 enrollment
November 2019 Phase 2 started.
MAT2203
Seems to have been abandoned for everything but cryptococcal meningitis
July 2019 Phase 1/2 trial started for cryptococcal meningitis
Both companies with low cash on hand and few assets.
CEO of Matinas, Jerome D. Jabbour's compensation $1.25 million (2018).
CEO of Cytodyn Nader Z. Pourhassan's compensation $837 thousand + 683 thousand bonus $1.52 million (2019).
Yet constant criticism from day 1 about Nader, yet none about Jerome.
Cytodyn
Leronlimab
May 2014 first patient dosed with Pro 140
December 2019 BLA nearing completion, FDA approval expected early 2nd quarter 2020
Matinas Biopharma
MAT9001
Dec 2014 enrollment
November 2019 Phase 2 started.
MAT2203
Seems to have been abandoned for everything but cryptococcal meningitis
July 2019 Phase 1/2 trial started for cryptococcal meningitis
Both companies with low cash on hand and few assets.
CEO of Matinas, Jerome D. Jabbour's compensation $1.25 million (2018).
CEO of Cytodyn Nader Z. Pourhassan's compensation $837 thousand + 683 thousand bonus $1.52 million (2019).
Yet constant criticism from day 1 about Nader, yet none about Jerome.
2